Thermo Fisher Scientific (NYSE:TMO) Announces Earnings Results, Beats Expectations By $0.24 EPS

Thermo Fisher Scientific (NYSE:TMO) announced its earnings results on Wednesday. The medical research company reported $5.37 earnings per share for the quarter, beating the consensus estimate of $5.13 by $0.24, Briefing.com reports. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The business had revenue of $10.54 billion for the quarter, compared to the consensus estimate of $10.50 billion. During the same quarter in the prior year, the firm posted $5.15 earnings per share. The business’s revenue for the quarter was down 1.4% on a year-over-year basis. Thermo Fisher Scientific updated its FY 2024 guidance to 21.290-22.070 EPS and its FY24 guidance to $21.29-22.07 EPS.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock traded up $14.93 during mid-day trading on Friday, reaching $609.43. 1,538,288 shares of the company traded hands, compared to its average volume of 1,556,319. Thermo Fisher Scientific has a fifty-two week low of $415.60 and a fifty-two week high of $614.60. The firm’s fifty day moving average is $562.77 and its two-hundred day moving average is $565.19. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.72 and a quick ratio of 1.33. The company has a market capitalization of $232.63 billion, a price-to-earnings ratio of 38.13, a price-to-earnings-growth ratio of 2.68 and a beta of 0.77.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be given a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 0.26%. The ex-dividend date of this dividend is Friday, September 13th. Thermo Fisher Scientific’s payout ratio is currently 10.01%.

Analyst Ratings Changes

Several research analysts have issued reports on TMO shares. JPMorgan Chase & Co. boosted their target price on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research report on Thursday, April 25th. Raymond James boosted their price objective on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an “outperform” rating in a research report on Thursday. Evercore ISI decreased their price target on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. Stifel Nicolaus raised their price objective on Thermo Fisher Scientific from $600.00 to $615.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Royal Bank of Canada lifted their price objective on Thermo Fisher Scientific from $660.00 to $664.00 and gave the company an “outperform” rating in a report on Thursday. Five equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $618.94.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the sale, the chief executive officer now owns 123,816 shares in the company, valued at approximately $70,238,340.48. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.34% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.